AU2017265839B2 - Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia - Google Patents

Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia Download PDF

Info

Publication number
AU2017265839B2
AU2017265839B2 AU2017265839A AU2017265839A AU2017265839B2 AU 2017265839 B2 AU2017265839 B2 AU 2017265839B2 AU 2017265839 A AU2017265839 A AU 2017265839A AU 2017265839 A AU2017265839 A AU 2017265839A AU 2017265839 B2 AU2017265839 B2 AU 2017265839B2
Authority
AU
Australia
Prior art keywords
fibromyalgia
formula
group
carbamate compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017265839A
Other languages
English (en)
Other versions
AU2017265839A1 (en
Inventor
Sun Gwan Hwang
Min Jae Jo
Han Ju Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2017265839A1 publication Critical patent/AU2017265839A1/en
Application granted granted Critical
Publication of AU2017265839B2 publication Critical patent/AU2017265839B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2017265839A 2016-05-19 2017-05-18 Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia Active AU2017265839B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0061392 2016-05-19
KR20160061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
AU2017265839A1 AU2017265839A1 (en) 2018-12-13
AU2017265839B2 true AU2017265839B2 (en) 2022-10-27

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017265839A Active AU2017265839B2 (en) 2016-05-19 2017-05-18 Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Country Status (14)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
CA (1) CA3024286A1 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033531B2 (en) * 2016-12-14 2021-06-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
US20200352907A1 (en) 2017-11-14 2020-11-12 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
US11666554B2 (en) * 2017-11-14 2023-06-06 Sk Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
WO2020080866A1 (ko) * 2018-10-19 2020-04-23 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
CA3157788A1 (en) * 2019-11-22 2021-05-27 Ji Hye Lee Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20100323410A1 (en) * 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) * 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
ES2278035T3 (es) * 2001-07-16 2007-08-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos de carbamato destinados a ser utilizados en la prevencion o el tratamiento del dolor neuropatico y del dolor asociado a las cefaleas agrupadas y por migrañas.
ES2743153T3 (es) * 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20100323410A1 (en) * 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) * 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIALER M., et al.; "Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)" Epilepsy Research, 2010, vol. 92, pages 89-124. *

Also Published As

Publication number Publication date
MX2018014080A (es) 2019-04-04
JP2019516707A (ja) 2019-06-20
KR102489052B1 (ko) 2023-01-16
KR20170131242A (ko) 2017-11-29
CN109475529B (zh) 2022-02-22
EP3459543A4 (en) 2020-01-15
RU2018144785A3 (enExample) 2020-08-11
RU2018144785A (ru) 2020-06-19
MX394245B (es) 2025-03-19
RU2753525C2 (ru) 2021-08-17
CN109475529A (zh) 2019-03-15
CA3024286A1 (en) 2017-11-23
EP3459543A1 (en) 2019-03-27
DK3459543T3 (da) 2023-02-13
BR112018073553A2 (pt) 2019-03-19
JP7071287B2 (ja) 2022-05-18
US10849882B2 (en) 2020-12-01
US20190298694A1 (en) 2019-10-03
EP3459543B1 (en) 2022-12-21
WO2017200318A1 (ko) 2017-11-23
AU2017265839A1 (en) 2018-12-13
ES2935596T3 (es) 2023-03-08
PL3459543T3 (pl) 2023-04-11

Similar Documents

Publication Publication Date Title
AU2017265839B2 (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
US20220087976A1 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
US10456376B2 (en) Use of carbamate compound in order to preventatively treat headaches
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US12070448B2 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
IL274428B2 (en) Use of a carbamate compound to prevent, relieve or treat a withdrawal seizure or epilepsy presenting with a withdrawal seizure
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
AU2019361856B2 (en) Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
BR112018073556B1 (pt) Uso de um composto de carbamato

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)